The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

As for Nuvaxovid, this standalone Novavax Covid-19 vaccine received its FDA approval in May, a regulatory decision that covers its use in those age 65 and older.

Moderna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 ...

The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active immunization to prevent COVID-19 caused by SARS-Cov-2 in adults 65 years and older and ...

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

(RTTNews) - Novavax, Inc. (NVAX) announced Monday that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid for active immunization to ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.Biologics License Application approval triggers $175 million Sanofi milestone payment, with ...

Novavax shares surged more than 17% before the bell on Monday, ... Nuvaxovid, but limited its use to older adults and people over 12 years with conditions that put them at risk due to the illness.